BioOutsource Global Expansion
BioOutsource Ltd has announced that the last 12 months have been an exceptional growth year for the company. Global demand for outsourced testing services, coupled with BioOutsource’s continued investment in R&D and the opening of a state of the art BioSimilar Centre of Excellence in Glasgow in February 2014, has driven continued development of the company and created the need to establish a new North American Testing Facility in 2015.
BioOutsource revenues have grown by more than 40% over the last 12 months with positive growth delivered across all business units. The company continues to strengthen and reinforce its position as market leader in the biological analysis of biosimilar molecules.
BioOutsource CEO, Gerry MacKay commented: “This year has been an exceptional year for BioOutsource, as we continue to grow and win more market share. Our biggest growth market has without doubt been North America, where we have seen sales triple in the past year.”
Following the successful opening of a US office in 2013, based in the BioTechnology Hub of Cambridge, MA, the company plans to open a Laboratory Facility in the Massachusetts area in early 2015 to service their North American & Latin American clients. The new Laboratory Facility will support and strengthen the company’s BioSimilar and BioSafety service offering.
“North America has always been an essential strategic element of our global expansion plans, exemplified by our US office and active membership of MassBio. We are already a global company and the time is right to extend our global client footprint with the addition of a new facility in the US. The new facility will benefit our existing and new clients, improving logistics and ensuring our technical experts are close by.”
Robert K. Coughlin, President & CEO of MassBio commented: “We are excited to welcome Gerry and his team to Massachusetts, as the gateway into business in the US.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.